# Sara López-Tarruella

Source: https://onco.cc/people/sara-lopez-tarruella/  
OnCo record `sara-lopez-tarruella` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Sara López-Tarruella is a breast oncologist leading GEICAM neoadjuvant studies in triple-negative disease.

## Summary

Sara López-Tarruella is a medical oncologist at Hospital General Universitario Gregorio Marañón in Madrid. Her specialisms are breast cancer, triple-negative disease and neoadjuvant trials, and she leads GEICAM neoadjuvant studies of chemotherapy and immunotherapy in triple-negative and HER2-positive breast cancer. Her papers include a Future Oncology piece on how to treat HR-positive, HER2-negative early breast cancer, a study of docetaxel, carboplatin and doxorubicin activity in patient-derived triple-negative xenografts, and an Annals of Oncology report on the TNBC-DX genomic test in early triple-negative breast cancer treated with neoadjuvant taxane-based therapy. Her publications are listed on PubMed.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Medical Oncologist, Hospital General Universitario Gregorio Marañón
- Specialisms: Breast cancer; Triple-negative disease; Neoadjuvant trials

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Lopez-Tarruella%20S%5BAuthor%5D%20breast%20neoadjuvant

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- institutions: [Hospital General Universitario Gregorio Marañón](https://onco.cc/institutions/gregorio-maranon/)
- journals: [Future oncology](https://onco.cc/journals/future-oncology/)
- companies: [GEICAM Spanish Breast Cancer Group](https://onco.cc/companies/geicam/)

---
JSON: https://onco.cc/api/v1/entities/sara-lopez-tarruella.json